In situ hybridization (ISH) assay services to support pre-clinical and clinical studies for pharma and biotech partners globally.
It offers:
These are performed by a dedicated team of highly trained specialists, scientists, and board-certified pathologists.
With direct access to the developers of the technology, the Assay Services team provides unparalleled expertise in our ISH platform and delivers fast, high quality data designed to meet your study objectives and timelines.
With 10 years of experience as a contract research organization (CRO) specializing in RNAscope™ ISH.
We have supported thousands of clinical and pre-clinical projects with every major biopharma in the United States and globally.
Each project is individually tailored and managed by our team of scientists, specialists, board certified pathologists, and data experts
View an example of an abridged biomarker assay dataset
generated for Wilms tumor 1 (WT1), a cancer vaccine target
There is growing interest in RNA-based biomarkers and measuring RNA expression holds great promise for stratifying patients based on drug response, drug efficacy and risk of side effects.
RNAscope in situ hybridization:
ACD's biomarker assays have contributed to important clinical trial exploratory endpoints, enabled more accurate patient selection, and spearheaded CDx development with our partner, Leica Biosystems.
ACD RNAscope for Biomarkers CDx Webinar Dr Christopher Bunker
The established workflow includes assay development and optimization followed by demonstration of specificity and sensitivity, stability, robustness, repeatability and intermediate precision, and other validation parameters.
Our scientists produce a detailed technical report describing the assay conditions optimized for the tissues of interest.
Our Field Application Specialist will work closely with your team to ensure successful training of the protocol and enable a faster transfer into your lab or external lab of your choice.
For Phase II clinical trials and beyond, our CLIA-Certified RNAscope™ Service Provider program is designed to support clinical trials for Advanced Cell Diagnostics’ leading pharmaceutical clients.
To view certified laboratories, please follow this link: https://acdbio.com/biopharma-partners
Are you interested to provide RNAscope services locally?
ACD offers a certification procedure to qualified labs to enable them to provide RNAscope™ services.
Each service provider undergoes:
> comprehensive training on RNAscope technology, which includes all aspects from sample preparation, quality control, assay procedure, data interpretation and analysis.
> Following the training, the lab is required to independently run the assay and send data for review at ACD.
Cell therapy services is offered in our Good Clinical Laboratory Practices (GCLP) compliant Professional Assay Services laboratory.
RNAscope is the only assay that can specifically detection engineered cell therapies and measure target engagement in intact human tumour biopsies.
CAR-T and TCR-T cell therapy probes consisting of pooled (“ZZ”) oligos targeting viral untranslated regions (UTRs) of CAR and TCR mRNA
RNAscope in situ Assays of Cell Therapy in Solid Tumors, Tumor Infiltration and Activation
Adeno-associated virus (AAV) has proven to be an effective gene therapy delivery vehicle. The primary considerations in gene therapy preclinical in vivo animal studies are:
• vector biodistribution,
• cell-specific uptake
• transgene expression
• safety against germ line transmission.
While assays of extracted RNA and DNA from bulk tissue are simple, these provide only an average value for an entire complex tissue and lack cellular resolution.
RNA and DNA in situ hybridization using RNAscope™ and BaseScope™ assays combine the quantitative, molecular measurement, like PCR, with single-cell resolution in the context of intact tissue morphology.
Moreover, RNAscope enables simultaneous detection of AAV vector DNA and transgene mRNA expression, and it can be multiplexed with cell markers. It is a simple and reliable method for analysis of AAV in routine FFPE tissues.
Capabilities:
• AAV vector DNA detection and quantification in intact fixed tissue
• Probes designed to AAV promoter regions and anti-sense strand from AAV DNA detection
• Detection of therapeutic human- and codon-optimized transgene RNA without cross-hybridization to endogenous transcripts
• Morphology-based AAV vector biodistribution and transgene mRNA expression analysis in intact animal model tissues
• Visual and quantifiable assays to measure percentage of cells positive for vector and transgene expression
• Multiplexed analysis of cell-specific AAV and transgene mRNA with cell marker probes.
Visual detection and quantification of AAV and LV vector biodistribution and transgene expression in preclinical animal models with RNAscope and BaseScope™ in situ hybridization.